- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
Patent holdings for IPC class C07D 319/18
Total number of patents in this class: 272
10-year publication summary
|
22
|
20
|
15
|
24
|
19
|
16
|
13
|
17
|
23
|
6
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 171 |
10 |
| CHDI Foundation, Inc. | 108 |
9 |
| Agios Pharmaceuticals, Inc | 216 |
6 |
| Merck Patent GmbH | 5873 |
5 |
| Cancer Research Technology Limited | 518 |
5 |
| Genzyme Corporation | 1242 |
5 |
| The Scripps Research Institute | 1347 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 868 |
5 |
| Toyama Chemical Co., Ltd. | 102 |
5 |
| Enveric Biosciences Canada Inc. | 62 |
5 |
| Lapix Therapeutics, Inc. | 17 |
5 |
| Bristol-myers Squibb Company | 4879 |
4 |
| F. Hoffmann-La Roche AG | 7934 |
4 |
| Allergan, Inc. | 2356 |
4 |
| BioMarin Pharmaceutical Inc. | 377 |
4 |
| ChemoCentryx, Inc. | 387 |
4 |
| Exonhit Therapeutics SA | 27 |
4 |
| Tianjin Chasesun Pharmaceutical Co., Ltd | 13 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2842 |
4 |
| Boehringer Ingelheim International GmbH | 4697 |
3 |
| Other owners | 172 |